Proportional change of CD4+CD25+ regulatory T cells after lymphocyte therapy in unexplained recurrent spontaneous abortion patients.
OBJECTIVE
To investigate the proportional changes of CD4(+)CD25(+) regulatory T cells in peripheral blood after lymphocyte therapy in unexplained recurrent spontaneous abortion (URSA) patients.


METHODS
Prospective cohort study.


METHODS
University Hospital.


METHODS
Twenty-five URSA patients.


METHODS
Measurements of CD4(+)CD25(+) regulatory T cells in peripheral blood before and after paternal or third-party lymphocyte immunization.


METHODS
The proportion of CD4(+)CD25(bright) regulatory T cells and the percentage of CD25(bright) cells in the CD4(+) T-cell population.


RESULTS
The proportion of CD4(+)CD25(bright) T cells in peripheral blood from URSA patients was increased significantly after paternal or third-party lymphocyte immunization therapy, whereas the percentage of CD4(+)CD25(dim) cells were decreased significantly. The percentage of CD4(+)CD25(bright) cells in the CD4(+) T-cell population was significantly increased, and the proportion of CD4(+)CD25(bright) T cells was significantly higher in successfully pregnant women than in those with pregnancy loss after lymphocyte therapy.


CONCLUSIONS
Allogeneic lymphocyte therapy can enhance the percentage of CD4(+)CD25(bright) regulatory T cells in peripheral blood, therefore CD4(+)CD25(+) regulatory T cells may serve as a novel biomarker for monitoring allogeneic lymphocyte therapy in URSA patients.
Yang
Hui
H
Department of Obstetrics and Gynecology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China. yanghu.ya@163.com
Qiu
Lihua
L
Di
Wen
W
Zhao
Aiming
A
Chen
Guangjie
G
Hu
Ke
K
Lin
Qide
Q
D000026:Abortion, Habitual / Q000276:immunology* / Q000628:therapy*; D000022:Abortion, Spontaneous / Q000276:immunology* / Q000628:therapy*; D015703:Antigens, CD / Q000276:immunology; D001323:Autoantibodies / Q000276:immunology; D015704:CD4 Antigens / Q000276:immunology*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D053645:Interleukin-2 Receptor alpha Subunit / Q000276:immunology*; D017710:Lymphocyte Transfusion; D011247:Pregnancy; D011256:Pregnancy Outcome; D011446:Prospective Studies; D050378:T-Lymphocytes, Regulatory / Q000276:immunology* / Q000637:transplantation
D015703:Antigens, CD; D001323:Autoantibodies; D015704:CD4 Antigens; D053645:Interleukin-2 Receptor alpha Subunit